Microbial Impact on NeuroDegeneration in Alzheimer's Dementia: MIND-AD - INCLUDE Admin Suppl

微生物对阿尔茨海默氏痴呆症神经退行性变的影响：MIND-AD - 包括管理补充

基本信息

批准号：
10852264
负责人：
Brion S Maher
金额：
$ 37.33万
依托单位：
JOHNS HOPKINS UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-09-30 至 2026-05-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10852264
关键词：
2019-nCoV Acceleration Administrative Supplement Adult Alzheimer&apos s Disease Alzheimer&apos s disease pathology Alzheimer&apos s disease related dementia Alzheimer&apos s disease risk Antibodies Area Award Back Baltimore Biological Aging Biological Markers Blood Blood specimen COVID-19 Catchment Area Child Childhood Clinic Cognitive Cytomegalovirus Data Databases Dementia Diagnosis Disease Down Syndrome Enrollment Epidemiology Future Herpesvirus 1 Human Herpesvirus 2 Human Herpesvirus 4 Impaired cognition Individual Infection Longevity Measures Medical Medical Records Mental disorders Mid-Atlantic Region Mind Nerve Degeneration Parents Participant Patient Recruitments Persons Phenotype Polysomnography Prevalence Prevention Public Health Recontacts Registries Research Research Personnel Sampling Schools Sleep Toxoplasma gondii Virus Work aged cohort functional decline functional outcomes microbial mild cognitive impairment participant enrollment recruit social media

项目摘要

Consistent with NOT-OD-22-137, Availability of Administrative Supplements for the INCLUDE Project, we propose to recruit 500 adults with Down syndrome (DS) aged 18-39 in the mid- Atlantic area to create a cohort, per Component 2: “Assembly of a large cohort of individuals with Down syndrome across the lifespan to perform deep phenotyping and study co-existing conditions.” Our Co-Investigator, Dr. Capone, at the Kennedy Krieger Institute (KKI), has data dating back ~25 years on >500 individuals with DS who were then children (3-17yrs) and are now adults. He also has data on an additional ~1,000 who were seen as adults (18-35yr) whom we will recontact for purposes of enrollment. From all 500 participants, we will collect demographic data and next of kin contact information for enrollment in future studies, and we will request releases of medical records from outside of KKI. This registry will be used to enroll participants in a future R01, which, like the parent award (R01AG075996; MPIs Spira & Maher), will investigate the association of antibodies to common infections (HSV- 1, HSV-2, CMV, EBV, TOX, SARS-CoV-2) in blood with cognitive and functional outcomes, mild cognitive impairment (MCI-DS) and dementia diagnoses, blood-based AD biomarkers, and measures of accelerated biological aging in persons with DS. If we cannot recruit 500 participants from among Dr. Capone’s former participants, we will expand through the mid-Atlantic region via mailing lists, clinics, schools, social media, and snowball sampling. We will prioritize recruitment of participants from Dr. Capone’s KKI database with existing data from childhood on medical conditions, psychiatric disorders, cognitive/adaptive function, and sleep data from polysomnography. This work is a supplement to Wave 5.5 of the Baltimore Epidemiologic Catchment Area (ECA) Study, which is investigating associations of common infections with cognitive and functional outcomes, MCI and dementia diagnoses, blood-based AD biomarkers, and measures of accelerated biological aging in that cohort.

与 NOT-OD-22-137 一致，包括的行政补充的可用性项目中，我们建议招募 500 名年龄在 18-39 岁之间的唐氏综合症 (DS) 成年人。大西洋地区根据第 2 部分创建一个队列：“聚集一大群个体患有唐氏综合症的人在整个生命周期中进行深度表型分析并研究共存我们的联合研究员、肯尼迪克里格研究所 (KKI) 的卡彭博士有数据。可以追溯到大约 25 年前，超过 500 名 DS 患者当时还是儿童（3-17 岁），他还拥有另外约 1,000 名被视为成年人（18-35 岁）的数据。我们将在所有 500 名参与者中重新联系他们进行注册。收集人口统计数据和近亲联系信息以用于未来研究的注册，我们将要求 KKI 外部发布医疗记录。该登记处将被使用。招收未来 R01 的参与者，与家长奖 (R01AG075996; MPI Spira & Maher）将研究抗体与常见感染（HSV- 1、血液中的 HSV-2、CMV、EBV、TOX、SARS-CoV-2）具有认知和功能结果，轻度认知障碍 (MCI-DS) 和痴呆诊断、血液 AD DS 患者的生物标志物和加速生物衰老的措施。无法从卡彭博士的前参与者中招募 500 名参与者，我们将扩大规模通过邮件列表、诊所、学校、社交媒体和滚雪球穿过大西洋中部地区我们将优先从卡彭博士的 KKI 招募参与者。数据库包含儿童时期有关医疗状况、精神疾病、认知/适应性功能，以及来自多导睡眠图的睡眠数据这项工作是补充。巴尔的摩流行病学流域 (ECA) 研究第 5.5 波，该研究正在进行调查常见感染与认知和功能结果、MCI 和痴呆的关联诊断、基于血液的 AD 生物标志物以及加速生物衰老的测量队列。